secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-09-17T23:59:59+00:00
Accession:  0001493152-25-013815
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata reports statistically significant Phase 3 XYNGARI acne data vs placebo at EADV 2025
--------------------------------------------------------------------------------

- IGA 2-point reduction + clear/almost clear at Week 12: 29.4% XYNGARI vs 15.2% placebo (p<0.001).
- Mean inflammatory lesion count change at Week 12: -16.8 XYNGARI vs -13.1 placebo (p<0.001).
- Percent change in non-inflammatory lesions at Week 12: 48.3% XYNGARI vs 34.7% placebo (p<0.001).
- All secondary endpoints (IGA, inflammatory, non-inflammatory) statistically significant at Weeks 4, 8, and 12.
- Data presented at European Academy of Dermatology and Venereology Congress 2025 from ongoing Phase 3 STAR-1 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000149315225013815/0001493152-25-013815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000149315225013815/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-013815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer